{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:36:01Z","timestamp":1777937761934,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The coronavirus disease 2019 (COVID-19) pandemic offered an epidemiological opportunity to evaluate if isolation and masking affected John Cunningham (JC) virus transmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to assess the proportion of natalizumab-treated patients who converted to a positive anti-JCV antibody serostatus before and during the pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data from TYSABRI Outreach: Unified Commitment to Health (TOUCH) for 22,375 US patients treated with natalizumab with anti-JCV antibody records were assessed in epochs annually from 2017 to 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Pre-pandemic anti-JCV antibody serostatus change was observed for 7.4%\u20137.7%. During the first and second years of the pandemic, 7.3% and 7.2% of patients\u2019 serostatus changed, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The proportion of patients with anti-JCV antibody serostatus change did not significantly differ during the first 2\u2009years of the pandemic compared with prior years. In contrast to seasonal influenza, masking and social distancing had no discernable effect on JCV serostatus change.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585241232274","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T04:29:14Z","timestamp":1708921754000},"page":"888-892","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of social distancing measures on anti\u2013JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis"],"prefix":"10.1177","volume":"30","author":[{"given":"Stephen C","family":"Krieger","sequence":"first","affiliation":[{"name":"Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York, NY 10029, USA"},{"name":"Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susie","family":"Sinks","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furong","family":"Huang","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Steverson","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar J","family":"Kalina","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"White","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L","family":"Avila","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"bibr1-13524585241232274","doi-asserted-by":"publisher","DOI":"10.3390\/v12090969"},{"issue":"3","key":"bibr2-13524585241232274","first-page":"179","volume":"41","author":"Pietropaolo V","year":"2018","journal-title":"New Microbiol"},{"key":"bibr3-13524585241232274","unstructured":"Biogen. TYSABRI (natalizumab, Prescribing information). Cambridge, MA: Biogen, 2021."},{"key":"bibr4-13524585241232274","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24286"},{"key":"bibr5-13524585241232274","unstructured":"Centers for Disease Control Prevention. 2020\u20132021 flu season summary, https:\/\/www.cdc.gov\/flu\/season\/faq-flu-season-2020-2021.htm (accessed 8 February 2023)"},{"key":"bibr6-13524585241232274","doi-asserted-by":"publisher","DOI":"10.1086\/504947"},{"key":"bibr7-13524585241232274","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.02.002"},{"key":"bibr8-13524585241232274","doi-asserted-by":"publisher","DOI":"10.1057\/s41599-021-00767-0"},{"key":"bibr9-13524585241232274","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174005"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241232274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585241232274","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241232274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:14:29Z","timestamp":1777695269000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585241232274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1177\/13524585241232274"],"URL":"https:\/\/doi.org\/10.1177\/13524585241232274","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}